Ratos AB: Ratos divests Sophion Bioscience
(Thomson Reuters ONE) -
Press release, 11 May 2017
Ratos's subsidiary Sophion Holding AB has entered into an agreement to divest
all of its shares in Sophion Bioscience A/S to Sapphire Bioscience Holding ApS,
a newly established company controlled by Thais Johansen, CEO of Sophion
Bioscience A/S. The sale is not expected to generate any significant exit
results for Ratos.
Sophion Bioscience previously formed one of two business areas in Ratos's
subsidiary Biolin Scientific, the second of which, Analytical Instruments, was
divested in December 2016. Following the divestment of Analytical Instruments,
Sophion Bioscience has been operated as an independent company in Ratos and
recognised in other net assets in the Ratos Group. Sophion Bioscience is a
Danish manufacturer in the area of Automated Patch Clamping (APC), and markets
instruments, test plates and support services. Customers include most major
pharmaceutical companies.
Given Thais Johansen's position as CEO of Sophion Bioscience, the transfer of
shares is covered by Chapter 16 of the Swedish Companies Act (so-called Leo
provisions) and is thus conditional upon the approval of Ratos's general meeting
of shareholders. The purchase price for all shares in Sophion Bioscience is SEK
60m. The company currently has about 50 employees and annual sales of
approximately SEK 100m. In recent years, the company has reported a declining
earnings trend and operating EBITA amounted to approximately SEK -0.6m in 2016.
The divestment is not expected to generate any significant exit results for
Ratos.
Notification of the Extraordinary General Meeting, scheduled to be held in June,
will be published in accordance with the provisions of the Swedish Companies
Act.
For further information, please contact:
Magnus Agervald, CEO Ratos, +46 8 700 17 00
Helene Gustafsson, Head of IR and Press Ratos, +46 8 700 17 98
Financial calendar from Ratos:
Interim report January-June 2017 17 August 2017
Interim report January-September 2017 14 November 2017
Ratos is an investment company that owns and develops unlisted medium-sized
companies in the Nordic countries. Our goal as an active owner is to contribute
to long-term and sustainable business development in the companies we invest in
and to make value-generating transactions. Ratos's portfolio consists of 17
medium-sized Nordic companies and the largest segments in terms of sales are
Construction, Industry and Consumer goods/retail. Ratos is listed on Nasdaq
Stockholm and has a total of approximately 14,200 employees.
Press release:
http://hugin.info/1180/R/2103822/798192.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ratos via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2017 - 10:11 Uhr
Sprache: Deutsch
News-ID 541791
Anzahl Zeichen: 3344
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ratos AB: Ratos divests Sophion Bioscience"
steht unter der journalistisch-redaktionellen Verantwortung von
Ratos (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
